PAR paradigm biopharmaceuticals limited..
Add to My Watchlist 7.53% ! 43.0¢

iPPS and the not so Looney comparison, page-6

  1. Mangoman605
    1,743 Posts.
    lightbulb Created with Sketch. 204
    clock Created with Sketch.
    23/08/21
    11:49
    Post #: 55494712
    The numbers are staggering IF there are no
    credible competitors appearing before and
    after FDA approval.

    We know of at least 2 probable competitors
    already in Phase 3.

    Can we just temper the bias confirmation
    for one minute?
    PAR Price at posting: $1.92 Sentiment: Hold Disclosure: Held
    Likes Created with Sketch. 4  Upvote
    lightbulb Created with Sketch.  Great analysis
    Stroke 3 Created with Sketch. Comments Created with Sketch. Reply

  2. Top Stories

 

Featured News

NEWS More Outstanding Gallium Assay Results for Nimy at Block 3
right-arrow Created with Sketch.
NEWS MTM Successful Uplisting Commences Trading on OTCQX Market in US
right-arrow Created with Sketch.
NEWS R&D Tax Refund of $5.8M Received by Imugene to Support Clinical Development
right-arrow Created with Sketch.
NEWS Austral Resources to Acquire Rocklands to Transform North-West Queensland Copper
right-arrow Created with Sketch.
NEWS Drilling Commences at Leinster South Project in WA
right-arrow Created with Sketch.
NEWS Paris Gold Project Drilling Underway Testing High-Grade Zones
right-arrow Created with Sketch.
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
Add to My Watchlist
(20min delay)
Last
43.0¢ 		Change
-0.035(7.53%) 		Mkt cap ! $170.8M
Open High Low Value Volume
47.0¢ 47.5¢ 42.0¢ $676.1K 1.519M

Buyers (Bids)

No. Vol. Price($)
2 16161 43.0¢
 

Sellers (Offers)

Price($) Vol. No.
44.5¢ 19584 1
View Market Depth
Last trade - 16.10pm 07/07/2025 (20 minute delay) ?
PAR (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.